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At present, strict and lifelong gluten-free diet is the only effective treatment for celiac dis-
ease. Even small amounts of gluten (50 mg/day) can be immunogenic; therefore all food and
food items and drugs that contain gluten and its derivatives must be eliminated completely
from the diet.While prescribing gluten-free diet is easy; the key to the success is the dietary
counseling by a nutrition specialist and maintenance of adherence to GFD by the patient.
In recent times, a number of targets to halt the process of immunological injury have
been explored to find out alternative treatment for celiac disease. These targets include
exploration of ancient wheat if they are less immunogenic, intra-luminal digestion of gluten
using prolylendopeptidases, pretreatment of whole gluten with bacterial-derived peptidase
before ingestion; prevention of passage of immunogenic peptides through the tight junc-
tions such as zonulin antagonists, Blocking of HLA-DQ2 to prevent binding of immunogenic
peptides, inhibition of transglutaminase 2, immune-modulation, and induction of tolerance
to gluten using gluten tolerizing vaccines, use of gluten-sequestering polymers, use of anti-
inflammatory drugs (glucocorticoids, budesonides) and anti-cytokines such as anti TNF-α,
and anti-interleukin-15. While many of these targets are still in the pre-clinical phase, some
of them including zonulin antagonist and endopeptidases have already reached phase II
and phase III clinical trials. Furthermore, while these targets appear very exciting; they at
best are likely to be used as adjunctive therapy rather than a complete replacement for
gluten-free diet.
Keywords: zonulin antagonist, gluten-free, HLA-blockers, transglutaminase inhibitor, probiotics, endopeptidases,
glucocorticoids, ancient wheat
INTRODUCTION
At present, strict and lifelong gluten-free diet is the only effec-
tive treatment for celiac disease (1). Even small amounts of gluten
(50 mg/day) can be immunogenic; therefore all food and food
items and drugs that contain gluten and its derivatives must be
eliminated from the diet completely (2). While prescribing gluten-
free diet is easy; the key to the success is the dietary education by a
nutrition specialist and maintenance of adherence by the patient
(3). Patients should be encouraged to join a celiac disease sup-
port group, because members of the support group are generally
more knowledgeable and adhere to their diet better than non-
members. The support group provides platform to discuss and
share many diet related issues and they learn from the experience
of the other members. The overall target of treatment of celiac
disease are summarized in Box 1.
EVOLUTION OF DIETARY MANAGEMENT OF CELIAC DISEASE
Dietary management was a mainstay of treatment of celiac dis-
ease even in the early part of the twentieth century (4). During
1930s, clinical improvement was observed with several differing
diets including a Dutch mussels diet suggested by Gee and the
banana diet popularized by Haas (5). Stools of such patients were
quiet greasy and worsening of their diarrhea after a carbohy-
drate diet led to another dietary approaches such as reduction
or almost complete elimination of dietary fat or carbohydrates.
During that time, the mortality of patients with celiac disease was
very high.
Then came a remarkable observation by a Dutch pediatrician
Willem Dicke who gave the birth to an idea from listening to one of
his child patients’ mothers. The mother of the patient told Willem
Dicke that her child used to become better if he did not eat wheat
products. From a clinical observation of one child and through
years of historical questioning and empirical dietary therapy, he
concluded that wheat was the toxic agent leading to celiac disease
(6). He then wrote his thesis on a remarkably careful series of
clinical studies, which resulted in basic understanding of the toxic
effects of wheat protein in celiac disease (7). We can only admire
and learn from such great physicians with superb clinical acu-
men whose observations led to great discoveries. Toward the end
of World War II, the so-called “winter of starvation” when even
bread was not available in Holland; children with celiac disease
paradoxically improved even though they were consuming a star-
vation diet (almost devoid of wheat products). When bread was
airdropped in Holland, these children rapidly deteriorated. Such
an observation further strengthened the idea that ingredients of
wheat were toxic agent for celiac disease.
Having initially established that removal of dietary whole
wheat products regularly improved symptoms and growth retar-
dation, Dicke studied the effect on his patients of other grains
and wheat components including rye flour, wheat flour, wheat
starch, rice flour, and cornstarch, each for several weeks at a
time. Following the observations of the effect of different diets
in celiac disease patients, Dicke published his work in 1953 (7).
Since>40% of amino-acid contents of gliadin was glutamine, the
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Box 1 The overall target of treatment of celiac disease.
Induction of remission
Clinical:
Resolution of symptoms
Improvement in the quality of life
Serological: Normalization of the titer of anti-celiac
antibodies
Histological: Reversal of histological abnormalities
Avoidance of long-term complications
Maintenance of remission by continuation of
gluten-free diet
Screening of the family members for celiac disease
Secondary prevention
Early detection of diseases and early institution of treatment
demonstration that deamidation of gliadin with hydrochloric acid
and subsequently and use of deamidated gliadin abolishing the ill
effects of gliadin further confirmed that, gliadin fraction of wheat
was possibly the pathogenic component (8). This was how, it was
established that gluten is the pathogenic agent for celiac disease.
WHAT IS GFD?
The philosophy behind the GFD has varied across the world
according to the strictness of what is considered “gluten-free” (9).
In Australia and New Zealand, a “no-detectable gluten” diet is
taught. This defines a gluten-free food as one in which gluten can-
not be detected by the most sensitive validated assay and equates
to about 2–5 ppm. In 2012, the level of gluten in foods that could
be considered gluten-free was redefined as 20 ppm (mg/kg), with
“very low gluten” foods defined as those <100 ppm (10).
HOWMUCH GLUTEN IS TOXIC?
Gluten intake varies from population to population and depends
upon dietary practices. A typical North Indian diet, where flat
bread is the usual meal, contains about 25–30 g gluten per day;
whereas average gluten intake in the West varies from 10 to
20 g/day. In a double blind, placebo-controlled prospective study;
Catassi et al. (2) demonstrated that an intake of as little as 50 mg
of gluten per day for 3 months was sufficient to cause a signifi-
cant decrease in the intestinal mucosal villous height/crypt depth
ratio. Furthermore, a daily intake of gluten of lower than 10 mg is
unlikely to produce significant histological abnormalities (11). The
gluten-free diet with the threshold at<20 ppm of gluten ensures an
intake of<50 mg/day and provides a sufficient safety margin (12).
GLUTEN IS UBIQUITOUS IN FOOD PRODUCTS
Gluten is responsible for most of the visco-elastic properties of
wheat flour doughs, which helps in making good breads. Because
of its visco-elastic properties, gluten is used extensively in the food
industry. In fact, efforts have been made to increase the gluten
content of the wheat by many wheat scientists. Globally, gluten
industry is quiet large and there is a big market for gluten. It may
be surprising to know that gluten is present in daily use item such
as lipsticks,postage stamps,beer, ice-creams, sweets, confectionary,
and many more (13).
With such widespread use of gluten in food items, it is therefore
extremely difficult to avoid gluten ingestion completely. Because
of lack of gluten labeling on the food items, it becomes almost
impossible to know if the particular product has gluten or not.
Almost half of patients with celiac disease continue to have active
disease despite following gluten-free diet (14). We also observed
that most of the patients continue to have varying grade of vil-
lous atrophy despite continuing on gluten-free diet from 1 to
4 years (15).
The management of celiac disease is truely different and unique
from the treatment of other medical or surgical diseases. The cen-
ter stage of treatment of celiac disease is dietary counseling of
the patient and the family by a nutrition specialist and a regular
reinforcement for adherence. The dietary councilor should have
sufficient knowledge about the food and food products. It is not
only about prescribing gluten-free diet but also is to provide an
individual patient specific well balanced diet. There are not enough
trained nutrition specialists in India. While a physician can diag-
nose the disease; he/she may not have sufficient knowledge or time
to explain to the patient about gluten-free diet; and therefore a
nutrition specialist/dietician must be involved in the management
of such patients.
RESPONSE TO GFD
Most patients with celiac disease respond to gluten-free diet within
weeks to months. Patients first start feeling an overall wellbe-
ing; symptoms of anemia, nutritional deficiencies start improving
within weeks. The normalization of hemoglobin and complete
recovery from diarrhea might take months. The adolescent and
children starts gaining their height within months. There is a pro-
gressive decrease in the titer of celiac related antibodies. While
mucosal healing is the ultimate goal of the therapy, the complete
healing of the mucosa is achieved in a minority of adults although
it is usual in children (11, 16).
ADHERENCE TO GFD
Wheat is consumed worldwide and gluten is constituents of diet in
many and varied forms. Since gluten is ubiquitous and used exten-
sively in the food industry, many food items may be contaminated
with gluten (17). Even the homemade food may get contaminated
with traces or even moderate amount of gluten (18). Furthermore,
even a small amount of gluten is immunogenic to the suscepti-
ble host. Maintenance of gluten-free diet is quiet demanding and
requires considerable amount of motivation by the patient and
the family. There is, thus, a need to develop alterative/adjuvant
therapies for the patients with celiac disease.
Patients with celiac disease diagnosed in their early part of life
comply better to GFD regimen than those who are diagnosed in
the adulthood. The compliance to GFD is generally poor in those
who have minimal symptoms or are diagnosed on screening than
those who have overt symptoms (19). Adherence to a gluten-free
diet is improved in individuals with a thorough understanding of
the diet and also those who participate in a celiac disease advocacy
group (20). As the patient grows from childhood to adulthood
and become asymptomatic, the compliance gets worse in adult-
hood. The reasons for non-compliance are poor palatability, cost,
availability, and social pressures (21). Non-appearance of acute
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symptoms after inadvertent or deliberate ingestion of gluten might
make the patient more confident and induce them to try gluten at
other occasions also. Many patients in remission might try gluten
to see what happens to them with gluten intake.
We need to emphasize to patients that symptoms and disease are
two different aspects. Disease might have to be advanced before
symptom arises and most patients may not develop symptoms
with occasional ingestion of gluten. Even occasional intake of
gluten in patients with celiac disease can maintain the immuno-
logical cascade of events and the inflammation in the intes-
tine. The nature and natural history of persistence of low-grade
inflammation is not known at the present time.
Patients on gluten-free diet may have significant negative
impact on their quality of life. They may feel socially retracted.
Furthermore, these patients have produce considerable psycho-
logical, emotional, and economic stress (22). Furthermore, non-
availability of GFD, while traveling, make them avoid both
professional and social commitments.
A small group of patients with celiac disease (2–5%) fail to
improve clinically and histologically upon elimination of dietary
gluten. This complication is referred to as refractory CD, and it
imposes a serious risk for developing lethal enteropathy-associated
T cell lymphoma (23).
NON-AVAILABILITY OF GLUTEN-FREE FOOD PRODUCTS
The families of patients with celiac disease can prepare gluten-free
food at home by learning the ways to avoid gluten contamination.
Furthermore, gluten-free food can be made available commer-
cially. Commercially available GFD are of two types, those having
limited shelf-life (gluten-free breads, biscuits, cakes, etc.), and oth-
ers having a relatively longer shelf-life. At present, gluten-free
products are not widely and freely available; they are expensive
and have poor shelf-life. There is a limited availability of gluten-
free products in India. There is an urgent need for gluten-free
foods in India and both food technology institutions and the food
industry should get involved.
NEED FOR AN ALTERNATIVE TREATMENT FOR CELIAC
DISEASE
Since gluten is ubiquitous and used extensively in the food indus-
try, many food items may be contaminated with gluten. Even the
homemade food may get contaminated with traces or even mod-
erate amount of gluten. We should remember that even a small
amount of gluten is immunogenic to the susceptible host. Main-
tenance of GFD is quiet demanding and requires considerable
amount of motivation by the patient and the family. There is thus
a need to develop alterative/adjuvant therapies for the patients
with celiac disease.
The gluten ingestion varies from population to population.
While most people in the west ingest about 13–15 g of gluten per
day; the gluten ingestion is higher especially in the Northern part
of India and averages about 20–30 g gluten per day (24). Such
large dose of gluten in a normal diet is less likely to be neutralized
by any form of alternative therapy. Therefore, one should realize
that GFD is the best and ideal for patients with celiac disease. The
potential alternative targets, which are presently investigated, are
expected to neutralize only a small amount of gluten exposure
(say 1–3 g of gluten per day) rather than 10–30 g of gluten. There-
fore, such agents will protect patients from minor unintentional or
unavoidable gluten ingestion rather than complete neutralization
of total gluten intake of a normal individual.
EMERGING THERAPY FOR CELIAC DISEASE
There are many targets in the inflammatory cascade of events,
which can be modulated in order to halt the process of immuno-
logical injury (25–30).
APPROACH 1: REDUCTION IN THE EXPOSURE OF GLUTEN
USE OF ANCIENT WHEAT
One of the approaches to decrease exposure to immunogenic
gluten in genetically susceptible person is to grow genetically
modified grains, which are devoid of immunogenic epitopes
(24, 25, 31). Although it looks very attractive, such an approach
however is very challenging. Gluten contains a large number of
immunogenic peptide, which can induce immune system in genet-
ically susceptible individuals (32). The genes coding for these
immunogenic peptides are located in different genetic loci in the
wheat genome, therefore gene silencing or gene deletion do not
appear to be the viable options.
Over the past five decades, several changes in the pattern of
wheat consumption has been observed including an increase in per
capita consumption of wheat, an increase in the use of gluten in
food processing and an increase in the consumption of processed
foods. Furthermore, an increase in celiac disease-related T cell
stimulatory epitopes has also been observed in the wheat. It is
conceivable that these changes in the wheat consumption pat-
tern and increase in T cells stimulatory epitopes in wheat may
be the reasons for an increase incidence of celiac disease world
over. It is be thus important to understand a bit about the genet-
ics of wheat and its immunogenic peptides involved in celiac
disease (33).
In the evolutionary process, the genome of wheat has changed
from diploid (14 chromosomes) to hexaploid genome (42 chro-
mosomes) (34). The genome of the most ancient wheat is diploid
and is called AA, BB, DD. These grass-like wheat species had a very
low seed yield and their seed dropped easily. Natural hybridiza-
tion between two of these diploid species led to birth of the
tetraploid Triticum species having AABB genome. Finally, around
4000 BC, natural hybridization between tetraploid (AABB) species
and diploid species (DD) led to origin of hexaploid wheat species.
Bread wheat (Triticum aestivum), the wheat used presently all
over the world, is an allohexaploid species resulting from nat-
ural hybridization between a tetraploid T. turgidum (dicoccum)
carrying the AABB genome and a wild diploid species Aegilops
tauschii carrying the D-genome. The introduction of the D-
genome in the wheat improved the bread-making properties of
the wheat (35, 36).
Most commonly used wheat at the present time is hexaploid
wheat (T. aestivum); and tetraploid wheat (Durum wheat) is
used sparingly. The immunogenicity of gluten peptides present
in various wheat varieties having diploid, tetraploid, or hexaploid
genome is different. Even amongst thousands of different Triticum
wheat varieties/accessions (hexaploid), the immunogenic poten-
tial may vary. These facts raised a question, if there is existence
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of safer/less immunogenic wheat varieties for patients with celiac
disease.
The gluten digest from the selected cultivars of Triticum
tauschii, the DD genome donor, contains all the T cell epi-
topes identified to be immunogenic in patients with celiac dis-
ease. Furthermore, isolation and characterization of intestinal
T cells from celiac disease patients have revealed several dis-
tinct but similar DQ2 and DQ8 epitopes. These epitopes are
generally very rich in proline and glutamine residues. The best
known and most immune-competent peptide for HLA-DQ2+
celiac disease patients is a 33-mer peptide encompassing 57–89
N-terminal region of certain α-gliadin proteins. This 33-mer pep-
tide is resistant to gastrointestinal proteolysis, does not require
intra-cellular processing for presentation, and binds efficiently to
HLA-DQ2 (37). Gluten, from the wheat having AA genome and
most likely also BB genome, lacks sequences equivalent to the 33-
mer immunogenic peptide fragment. Experiments with mutant
wheat lines suggest that most immunogenic peptide sequences are
encoded exclusively by γ-gliadin genes located on chromosome
6D (38). This explains why some durum wheat (AABB) cultivars
do not have these immunogenic peptides.
Overall the present set of evidences tends to suggest that the
ancient wheat cultivars are less immunogenic for patients with
celiac disease (39). Attempts to detoxify the gluten epitopes by a
number of different methods are being taken. Genetic deletion of
certain gliadin genes, notably the complete deletion of α-gliadin
in Chinese spring wheat, led to the decrease in the number of T
cell-activating epitopes without affecting the baking quality of the
wheat flour dough (40).
In fact, there are now efforts being made to decrease the
immunogenic gliadin peptides in wheat using RNA interference
technology (41).
There are many challenges in the process of the modification of
gluten contents in the wheat varieties and some of them are: (i) the
modifications in the protein contents may lead to loss and decrease
in baking characteristics, the main property of wheat, which makes
it a preferred cereal by the humans; (ii) all the immunogenic pep-
tides in wheat are still not known; and (iii) there is a potential
for contamination (if sown in nearby fields) of the future genet-
ically modified grains with the wild strains during cultivation,
pollination, harvesting, and processing.
APPROACH 2: ASSISTED DIGESTION OF GLUTEN
The principal of assisted digestion is to detoxify the gluten either
in the gastrointestinal lumen using endopeptidases (Intra-luminal
enzymatic digestion) or using predigested gluten where gluten is
digested partially before ingestion.
INTRA-LUMINAL ENZYMATIC THERAPY
Dietary proteins reaching the intestinal lumen are digested by
gastric pepsin and pancreatic proteases and further degraded by
brush border enzymes (dipeptidases, tripeptidases) into amino-
acid, dipeptides, or tripeptides, which are transported across the
enterocytes. The principal toxic components of gluten are proline-
and glutamine-rich peptides that are resistant to proteolysis by gas-
tric, pancreatic, and intestinal brush border membrane enzymes
(42). Human do not have enzyme to break the bond between
proline and glutamine. Therefore, gluten protein is not digested
completely and partial digestion of gluten leads to creation of
multiple peptides, which induce immune system in genetically
predisposed people and cause celiac disease (43).
Therefore, one of the logical approaches is to use enzyme(s)
that can break/digest the bond between proline and glutamine in
the gluten (25, 26, 28). Prolyl endopeptidases (PEPs) can break
bonds between proline and glutamine and can be derived from
microorganisms such as Flavobacterium meningosepticum, and
Sphingomonas capsulate (44). Most of these enzymes however, are
irreversibly inactivated in the stomach by pepsin and acidic pH,
and do not reach in the intestine in adequate concentration, and
thus require to be delivered in acid resistant capsule forms.
A combination of endoprotease B2, a glutamine-specific pro-
tease from germinating barley, and PEP from S. capsulata could
efficiently break down whole wheat gluten in vitro and in a rat
model in vivo, and abrogated largely its immunogenic potential
as assessed with several gluten-specific T cell lines (45–49). While
glutamine-specific endoproteases (EP-B2) hydrolyzed extensively
the gluten network present in the bread into relatively short (but
still inflammatory) oligopeptides; prolyl specific endopeptidase
from S. capsulata rapidly detoxified the oligopeptides after pri-
mary proteolysis at internal proline residue level to yield non-toxic
metabolites (50). Both these enzymes are active and remain sta-
ble at acid pH and can therefore be administered as lyophilized
powders or simple capsules or tablets (51).
ALV003 (developed by Alvine Pharmaceuticals) is a combina-
tion of two different gluten-targeting proteases (glutenases) with
complementary substrates. It contains a cysteine-endoprotease
derived from germinated barley seeds and a PEP from S. capsu-
lata. Both of them are active in acidic medium and their glutenase
activity is maximized in a 1:1 formulation. In a Phase 1 clinical
trial, 20 patients with celiac disease in remission were randomized
to receive a diet containing gluten (16 g/day for 3 days) pretreated
with ALV003 and a diet containing gluten and placebo. Patients
who received ALV003 gluten had significantly lower immunologi-
cal activation compared to the group that received placebo (52). A
subsequent phase 1b study showed that ALV003 was very effec-
tive, in the stomach, in breaking down food with high gluten
content (53).
In a double blind, placebo-controlled phase 2a clinical trial on
41 adults with celiac disease, on GFD for one or more years, were
randomized to ALV003 or a placebo each day for 6 weeks along
with 2 g of gluten in the form of bread crumbs. The small intesti-
nal mucosal injury, as measured by villous height/crypt depth
ratio, was significantly less in patients treated with ALV003 than
those treated with placebo (p= 0.0133). Intraepithelial lympho-
cytes including CD3+ and CD3+ alpha/beta and gamma/delta
subsets, which measure inflammatory response, were essen-
tially unchanged in the ALV003-treated patients but significantly
increased in the placebo-treated patients. No serious adverse
events were reported (54). Based on the encouraging preliminary
results on safety and efficacy at least in short terms; phase III study
is being planned using ALV003 as an adjunct therapy with GFD.
There are other sources for PEP and PEP derived from
Aspergillus niger has also been shown to degrade gluten peptides
(55, 56). Furthermore, PEP from A. niger (AN-PEP) is derived
Frontiers in Medicine | Gastroenterology March 2014 | Volume 1 | Article 6 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Makharia Current and emerging therapy for celiac disease
from the food grade microorganism and is available on an indus-
trial scale. In a cross-over, randomized, double blind, placebo-
controlled clinical trial, AN-PEP’s showed ability to detoxify 8 g
of gluten contained in a commercial food product when tested in
patients with celiac disease in remission (57).
Complete avoidance of gluten is very difficult since gluten is
so widely used in food and food products. While, enzyme therapy
can protect patients with celiac disease from unwanted or hidden
gluten or unwanted exposure to gluten but will not be effective in
digestion of normal dietary gluten intake.
PRETREATMENT OF WHOLE GLUTEN WITH BACTERIAL-DERIVED
PEPTIDASE BEFORE INGESTION
An alternative approach is to detoxify gluten by digestion of wheat
gluten and its peptides using bacteria-derived peptidases during
food processing. A few selected sourdough lactic acid bacteria are
used widely for fermentation of food in the food industry (58).
Certain selected lactobacilli added to sourdough for fermenta-
tion have been shown to lyse the proline/glutamine-rich gluten
peptides reducing their immunotoxicity (59, 60). Fermentation of
the wheat with sourdough lactobacilli led to decrease in the con-
centration of gluten to below 10 ppm as shown by Rizello (61).
Furthermore, a mixture of fermented wheat flour along with oat,
millet, and buckwheat, have been found to retain its baking char-
acteristics. Wheat flour-fermented with selected lactobacilli and
fungal proteases (routinely used in bakeries) led to decrease in
gluten content to<10 ppm (gluten-free). Eight patients with celiac
disease in remission were enrolled for the clinical challenge, and
they consumed 200 g/day of sweet baked goods equivalent to 10 g
of native gluten. One patient interrupted the trial after 15 days
and another after 30 days due to difficulties in the adherence to
daily consumption. None of the patients showed worsening in
hematological, serological parameters, and intestinal permeabil-
ity during 60 days of challenge. This study showed that a wheat
flour-fermented product, having gluten completely degraded, is
not toxic for patients with celiac disease (62).
In another study from Italy, patients were randomly assigned
to consumption of 200 g/day of natural flour baked goods
(NFBG) (80,127 ppm gluten; n = 6), extensively hydrolyzed flour
baked goods (S1BG) (2480 ppm residual gluten; n = 2), or fully
hydrolyzed baked goods (S2BG) (8 ppm residual gluten; n = 5)
for 60 days. Two of the six patients who consumed NFBG dis-
continued the challenge because of symptoms; all had increased
levels of anti-tissue transglutaminase antibodies and small bowel
deterioration. The two patients who ate the S1BG goods had
no clinical complaints but developed subtotal atrophy. The five
patients who ate the S2BG had no clinical complaints; their levels
of anti-tTG antibodies did not increase, and their Marsh grades of
small intestinal mucosa did not change (63).
Among probiotic preparations, VSL#3, a highly concentrated
mixture of lactic acid and bifidobacteria, was able to hydrolyze
completely theα2-gliadin derived epitopes 62–75 and 33-mer pep-
tide (64). Furthermore, probiotics have also been shown to directly
modulate the epithelial cells. Some probiotic strains, including
the VSL#3 preparation, increase the epithelial barrier function by
stabilizing tight junctions (65, 66).
APPROACH 3: PREVENTION OF PASSAGE OF IMMUNOGENIC
PEPTIDES THROUGH THE TIGHT JUNCTIONS
Tight junctions regulate the passage of molecules through inter-
cellular spaces between epithelial cells (paracellular transport).
Intercellular junctions are composed of tight junctions (most api-
cal), adherens junctions, gap junctions, and desmosomes. Tight
junctions are regulated by a number of cytoskeletal proteins
including trans-membrane proteins (claudin family, occludin,
junctional adhesion molecules) and cytoplasmic protein (ZO-1,
2, 3) (67). In normal conditions, harmful bacteria and dietary
antigens are prevented from passing through the tight junc-
tions. The function of tight junctions is assessed using intestinal
permeability (68).
Changes in the paracellular permeability have been hypothe-
sized to be an early event in the pathogenesis of celiac disease (24).
The immune system of susceptible individuals gets exposed to the
immuno-stimulatory gluten peptides, which passes through the
paracellular route (69). Human protein Zonulin, a precursor of
prehaptoglobin-2, has been found to be a regulator of epithelial
permeability and is highly expressed in the mucosa and blood of
patients with celiac disease (70). Zonulin, which is similar to a pro-
tein zonula occludens toxin (ZOT) expressed by Vibrio cholerae,
impairs epithelial tight junctions integrity. A recent study has
shown that gliadin binds to the chemokine receptor CXCR3 releas-
ing Zonulin and subsequently increases the intestinal permeability
via the MyD88 dependent pathway (71).
Larazotide acetate (AT-1001, developed by Alba Therapeutics,
USA) is an octapeptide derived from a cholera toxin, ZOT and has
been found to antagonize zonulin via receptor blockade (72, 73).
Larazotide acetate is expected to reduce the paracellular transport
caused by gluten and ameliorate the activation of the pathologi-
cal immune cascade. Six clinical trials have been completed with
larazotide acetate. Three of them were Phase 1 trials: two trials in
healthy individuals (one single-dose and other multiple dose safety
studies) and a third safety study in subjects with celiac disease. In
all these studies, the safety profile of larazotide was comparable to
that of the placebo (23).
Subsequently, three Phase II studies have been completed. In
a Phase IIa randomized, placebo-controlled double blind trial; 86
patients with celiac disease in remission were given gluten chal-
lenge of 800 mg 15 min after administration of AT-1001 or placebo,
three times a day for 2 weeks. While the primary endpoint of
improvement in intestinal paracellular permeability was not met;
the symptoms triggered by the 2-week gluten challenge were sig-
nificantly ameliorated by larazotide acetate (72). In the Phase IIb
study (randomized, placebo-controlled, double blind), different
doses of larazotide (1, 4, and 8 mg) were compared against placebo.
The study enrolled 184 patients with celiac disease in remission and
were subjected to a 6-week gluten challenge of 900 mg three times
a day. Again, larazotide acetate could not demonstrate statisti-
cally significant efficacy in the reduction in intestinal permeability,
though a favorable trend was observed (74). A new large (320
patients) Phase 2b study is on the way to study different doses (0.5,
1, and 2 mg/day) of larazotide acetate in patients with celiac disease
who are non-responsive to a GFD (ClinicalTrials.gov identifier:
NCT01396213).
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Increase in intestinal permeability is also dependent on Rho
kinase (ROCK) activity (75). In addition to regulating tight junc-
tion structure and function, Rho A and ROCK are known to
regulate axon growth. The benefit of blocking Rho A and ROCK
have been well documented for the treatment of spinal cord injury
(76). For example, fasudil, an inhibitor of ROCK, is an approved
drug in Japan for the treatment of cerebral vasospasm. Whereas
the side effect of fasudil makes it inappropriate for chronic, long-
term use in patients with celiac disease, the drug could be used
to establish whether ROCK inhibition can reverse gluten depen-
dent increased in intestinal permeability in patients with celiac
disease (25). If so, a number of next generation ROCK inhibitors
are under active evaluation for other indications such as asthma,
pulmonary hypertension, and multiple sclerosis, and some of
these drugs may hold promise as therapeutic agent for celiac
disease (25).
APPROACH 4: BLOCKING OF HLA-DQ2 TO PREVENT BINDING
OF IMMUNOGENIC PEPTIDES
As discussed in the previous sections, celiac disease is a genetic
disease and almost all of them have HLA-DQ2 and -DQ8 haplo-
type (77). Gluten peptides after passing through the intercellular
junctions get deamidated by enzyme transglutaminase 2 (TG2),
which are present in the subepithelial basement membrane. The
deamidated peptides become negatively charged and these charged
particles have affinity to bind to the grooves present on the HLA-
DQ2 and/or DQ8 located on the surface of antigen-presenting
cells. The antigen-presenting cells then leads to activation of T lym-
phocytes (adaptive immune response) (24). Therefore, blocking
the binding grooves of these HLA molecules by gliadin antago-
nist peptides could suppress the antigen presentation process and
block the further cascade of T cell stimulation.
The crystallographic structure of HLA-DQ2 and its complex
with a deamidated gluten peptide has provided important infor-
mation for the development of antagonist compounds. Amino-
acid substitutions within gliadin T cell stimulatory sequences can
convert the immunogenic epitope to either an agonist or antago-
nist. If antagonist, it can block the inflammatory cascade of events.
Ellis et al. (78) reported that substitution of alanine amino-acid
at key positions (3, 8, and 10) in the immunodominant peptide
of the wheat α2-gliadin (residues 62–75) led to abolition of the
immunogenicity of the peptide when tested against T cell clones.
In addition, a decapeptide (QQPQDAVQPF) obtained from an
alcohol-soluble protein fraction of durum wheat was shown to
be antagonistic to gluten toxicity in vitro (79). An aldehyde func-
tionalized gluten peptide analog has also been designed, which
acts both as a tight-binding HLA-DQ2 ligand and a high-affinity
reversible inhibitor of tTG2 (80).
While the concept of celiac-specific HLA inhibition is partic-
ularly attractive, there are substantial challenges including get-
ting access to the binding groove of the DQ2/DQ8 on antigen-
presenting cells and avoidance of rapid degradation of these
peptide agents during delivery. Interference with the immuno-
surveillance functions of HLA class 2 molecules by blocking
them in tissues others than intestine is an important point of
consideration.
APPROACH 5: INHIBITION OF TRANSGLUTAMINASE 2
Transglutaminase 2 is a ubiquitous multifunctional mammalian
protein that catalyzes the formation of intermolecular isopeptide
bonds between glutamine and lysine residues of a few selected
proteins (81). Its enzymatic activity is allosterically regulated by
several factors, including guanine nucleotides, Ca+2, and redox
potential. In the small intestinal mucosa of celiac disease patients,
TG2 deamidates glutamine residues of gluten peptides and create
potent T cell epitopes (82). TG2 also induces crosslinking of gluten
peptides with matrix proteins, thereby maintain gluten in the tis-
sue and generate complexes that induce an immune response to
additional auto-antigens. Therefore, TG2 inhibitors are thought
to have promising avenues for celiac disease therapy (25).
At present, there is no successful mouse model for celiac disease.
Therefore, most of the potential therapeutic targets are evaluated
on simplified biological systems. There are two notable ex vivo
experiments that suggest that TG2 inhibition have the potential
to benefit patients with celiac disease. In the first study, Molberg
et al. (83) showed that culture of small intestinal biopsies of celiac
disease patients with either TG2 treated (deamidated) or non-
TG2 treated (non-deamidated) gluten resulted in the generation
of T cell lines that preferentially recognized deamidated gluten
peptides rather than non-deamidated gluten peptides. Further-
more, blocking of the activity of endogenous TG2 in the biopsies
with cystamine led to reduction in proliferative responses, in more
than half of the T cell lines, to deamidated gluten digests com-
pared to non-cystamine treated controls. Taken together, these
two results imply that the gluten responsive T cell populations in
intestinal biopsies of celiac disease patients are naturally biased
toward recognizing deamidated gluten peptides as opposed to
non-deamidated peptides. Blockade of the activity of TG 2 by TG2
inhibitors can reduce the proliferative response of gluten-reactive
T cells in the intestine.
In another study, Maiuri et al. (84) showed that the 2-[(2-
oxopropyl)thio] imidazolium inhibitor, L682777, was able to pre-
vent the in situ crosslinking of gluten peptides to endogenous pro-
teins in thin tissue sections taken from both celiac disease patients
and controls. More importantly, they showed that incubation of
intact celiac small intestinal biopsies with L682777 prevented T cell
activation induced by the non-deamidated form of an immun-
odominant gluten peptide. In contrast, L682777 was ineffective
in controlling T cell activation when the biopsies were incubated
with the deamidated version of the same peptide. These results
suggest that irreversible inhibition of endogenous TG2 in celiac
disease patient biopsies can prevent gluten peptide deamidation
and, therefore, reduce T cell activation.
APPROACH 6: IMMUNE-MODULATION AND INDUCTION OF
TOLERANCE TO GLUTEN
Although gluten is a normal food ingredient however 1% of
the world’s population is unable to tolerate peptides of partially
digested gluten, which act as auto-antigens. Therefore, another
logical and attractive option to reverse the gluten intolerance is
to restore the tolerance to ingested gluten. Protein-based desen-
sitization therapy is often used to treat allergic diseases (85). For
example, peptide-based vaccination by intra-dermal injection of
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cat allergen peptides has shown efficacy in the treatment of cat
allergy (86).
NexVax2 is a desensitizing or therapeutic“vaccine”and is under
development by a biotechnology company ImmuSanT. NexVax2
uses three gluten peptides with the goal of inducing a“tolerogenic”
response in patients with celiac disease. NexVax2 has showed effi-
cacy in HLA-DQ2 transgenic mice having gluten-sensitive T cells
(87). In a phase 1 study, 40 well-controlled patients with celiac
disease were given subcutaneous injections of increasing doses
of up to 90µg of Nexvax 2 in weekly doses for 3 weeks. While
there were some gluten-related gastrointestinal side effects, dose
escalation could be completed and safety was acceptable. Vacci-
nated subjects showed presence of IFN-γ-producing anti-gluten
T cells (88).
The real efficacy of such a strategy is still to be established. Syn-
thetic peptide vaccines can be developed to include only a finite
number of known immunogenic gluten peptides. There are many
issues, such as efficacy and long-term safety, are to be established
before peptide vaccines are made available for the management of
celiac disease.
APPROACH 7: GLUTEN-SEQUESTERING POLYMER
Polymeric binders are used in various clinical disorders to
sequester toxic compounds in the gastrointestinal tract. Another
novel approach to block gluten toxicity using polymeric binder,
poly (hydroxyethyl methacrylate-co-styrene sulfonate) [P(HEMA-
co-SS)]. P(HEMA-co-SS) has been shown to complex with α-
gliadin in a relatively selective fashion (89, 90). The binder
counteracts the toxic effects of gliadin on intestinal epithelial
cells in vitro. Pinier (91) recently reported important findings
regarding the in vivo biodistribution and therapeutic efficacy
of P(HEMA-co-SS) when administered orally (single-dose and
repeated administration) in a mixture containing whole wheat
gluten and other food components to rodents. They showed that
P(HEMA-co-SS) hindered significantly the formation of major
identified immunogenic peptides from wheat gluten (such as
QLQPFPQPQLPY and LQPQQPFPQQPQQPFPQ) by gastroin-
testinal enzymes. P(HEMA-co-SS) was shown to also decrease the
production of immunogenic peptides from barley.
The mechanism of action of the polymeric binder may be more
complex in vivo, it is unknown whether similar degree of inhibi-
tion of the peptide can be achieved in vivo as achieved in vitro
experiments. Furthermore, polymeric binders may be useful only
for the inadvertent or minimal gluten exposure and have potential
role as supportive therapy rather than a complete treatment for
celiac disease.
APPROACH 8: ANTI-INFLAMMATORY DRUGS
Like inflammatory bowel disease and rheumatoid arthritis, celiac
disease is also an inflammatory disease. Several strategies target-
ing the involved cytokines, chemokines, and chemokine receptors
are being developed in relation with celiac disease. While most
patients with celiac disease respond to GFD, the scope for anti-
inflammatory drugs will be mainly for patients with refractory
celiac disease.
GLUCOCORTICOIDS
Glucocorticoids are not used for uncomplicated patients with
celiac disease and are generally reserved for celiac crisis, gliadin
shock, or refractory celiac disease. Reports on the inhibitory effect
of steroids on both B and T cell proliferation in in vitro stud-
ies or their effect on reduction of the lymphokine level released
by the cultured cells indicated that they may be effective if given
in addition to GFD to patients with celiac disease (92). Wall et al.
(93) showed an accelerated improvement in symptoms by addition
of prednisone to GFD in patients with celiac disease. In another
in vitro study, Mitchison et al. (94) had also demonstrated the
inhibitory effects of fluticasone propionate on the harmful effects
of gluten. In a more recent study on 20 patients with celiac disease,
Ciacci et al. (95) have shown a better clinical response in a group
of patients treated with a combination of GFD and budesonide for
4 weeks in comparison to those treated with GFD alone.
We conducted a proof of concept randomized control trial to
see the effects of short course of prednisolone along with GFD on
the markers of apoptosis and anti-apoptosis pathways, as well as
on epithelial cell regeneration in patients with celiac disease. Our
hypothesis was to see if addition of prednisolone for a short term,
accentuates the mucosal recovery. While addition of prednisolone
to GFD led to a significant reduction of apoptosis; it also led to
decrease in epithelial cell regeneration (96).
CYTOKINES AND CHEMOKINES
Anti-interferon-γ and anti TNF-α
The activation of gluten-sensitive CD4+ T cells leads to secretion
of IFN-γ, which triggers pro-inflammatory responses including
activation of metalloproteinases (MMPs) that results in mucosal
injury and villous atrophy. In a similar fashion, TNFα also triggers
a proteolytic cascade mediated by MMPs secretion from intestinal
myofibroblasts and results in intestinal architectural alteration.
Therefore, blockade of these cytokines may prevent the activa-
tion of proteolytic MMPs and ultimately resume the intestinal
hemostasis (24, 28). IFN-γ-blocking antibodies have been shown
to prevent damage to healthy intestinal mucosa exposed to the
inflammatory cytokines released by the gliadin-specific T cell lines
(97). It has also been demonstrated that gliadin-induced-IFN-γ
secretion increases gliadin influx through the intestinal barrier.
Thus, IFN-γ-blocking agents may stop this vicious cycle (98).
In anecdotal cases, monoclonal antibodies against TNF-α (inflix-
imab) has been shown to be beneficial for patients with severe
refractory celiac disease and refractory celiac disease (99, 100).
Anti-interleukin-15
Interleukin-15 (IL-15), secreted from the intestinal epithelium and
antigen-presenting cells in response to gliadin peptides, plays an
important role in the underlying innate immune response in the
intestinal mucosa of patients with celiac disease. It induces the
secretion of epithelial MICA that binds to NKG2D receptor located
on the surface of intraepithelial lymphocytes (101, 102). This
ligand receptor interaction is enhanced by IL-15, leading to stim-
ulation and proliferation of cytotoxic T lymphocytes that induce
epithelial apoptosis and also results in development of refractory
celiac disease and its malignant transformation (103). A study on
transgenic mouse models with overexpression of IL-15 and con-
sequent development of autoimmune enteropathy demonstrated
that blocking antibody against IL-15 was capable of efficiently
reversing the intestinal damage (28, 104). IL-15 also prevents
apoptosis of the cytotoxic intraepithelial lymphocytes that plays a
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central role in the refractory celiac disease via the JAK 3/STAT 5
signaling pathway. IL-15 blocking antibodies were able to induce
IEL apoptosis and reduce the number of IELs accumulated in
the intestinal epithelium of human IL-15 transgenic mouse model
(105). Anti-IL-15 human monoclonal antibody has been evaluated
in patients with other autoimmune disease such as rheumatoid
arthritis, but despite the promising findings, a human study for
celiac disease is still awaited.
Interleukin-10
Interleukin-10 (IL-10) is an immunoregulatory cytokine in the
intestinal tissue and suppresses inflammatory cytokine secre-
tion from TH1 cells. Therefore, IL-10 is considered as a can-
didate for the treatment of TH1-mediated autoimmune disor-
ders such as inflammatory bowel disease and celiac disease (24,
28). Although IL-10 was shown to suppress gliadin-induced T
cell activation in an ex vivo study of cultured intestinal biop-
sies for celiac disease (106), however a pilot study on patients
with refractory celiac disease did not show any pharmacological
efficacy (107).
Lymphocytic recruitment blockade
Integrin α4β7 and MAdCAM-1. For migration of lympho-
cyte to the site of inflammation (intestinal mucosa in case of
celiac disease), T cells express integrin (α4β7), which are required
for their binding to mucosal addressin cell adhesion molecule-
1 (MAdCAM-1) located on vascular endothelial cells (108).
MAdCAM-1 has been shown to be is significantly upregulated in
treatment naïve patients with celiac disease. Therefore, lympho-
cytic recruitment blockade using blockers of integrin (α4β7 and
MAdCAM-1) could be a potential therapeutic target for patients
with celiac disease (109). Furthermore, Natalizumab, a mono-
clonal antibody against α4 integrin, has already been shown to
be effective in patients with Crohn’s disease (110).
FUTURE
A better understanding of the pathogenesis of celiac disease and
realization that gluten-free food although the best but not com-
pletely acceptable has opened the gates for development of newer
targeted drugs. The development of drugs from the concept to
bench and from bench to clinical use takes many years and requires
an extremely large amount of money and resources. The alterna-
tive drug development in the field of celiac disease is still in the
early stages of drug discovery. In the past few years, a new novel tar-
gets have reached Phase I and Phase II trials and larger randomized
controlled trials are on the horizon.
COMMERCIAL SCOPE FOR PIPELINE DRUGS FOR CELIAC DISEASE
A GlobalData report based on the data and information sourced
from proprietary databases, primary and secondary research and
in-house analysis suggests that global celiac disease therapeutics
market will be of worth $512.3 million in 2017 (111). This market
is expected to grow at a compound annual growth rate of 13.9%
to reach $664.4 million by 2019. This high growth forecast is pri-
marily attributed to the increased uptake of the pipeline products
and increase in diagnosis rates.
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